Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

98 Press Releases
DateTitleCompany
25 Apr 17 AmpliPhi Biosciences Announces Presentation of Personalized Bacteriophage Therapy Case Study for Life-Threatening Antibiotic-Resistant Infection at Scientific Conference AmpliPhi Biosciences Corporation,
Published by
Business Wire
17 Apr 17 AmpliPhi Biosciences Announces Positive Feedback from FDA on Phase 2 Development Proposal AmpliPhi Biosciences,
Published by
Business Wire
14 Apr 17 AmpliPhi Biosciences Announces Planned One-for-Ten Reverse Stock Split AmpliPhi Biosciences Corporation,
Published by
Business Wire
04 Apr 17 AmpliPhi Biosciences Announces Presentations of Clinical and Preclinical Data from Studies with its Bacteriophage Technology at Two Scientific Conferences AmpliPhi Biosciences Corporation,
Published by
Business Wire
07 Mar 17 AmpliPhi Biosciences to Present at the 29th Annual ROTH Investor Conference AmpliPhi Biosciences Corporation,
Published by
Business Wire
23 Feb 17 AmpliPhi Biosciences Establishes Scientific Advisory Board and Appoints Dr. Timothy Lu of MIT and Broad Institute as SAB Chairman AmpliPhi Biosciences Corporation,
Published by
Business Wire
06 Feb 17 AmpliPhi Biosciences to Present at the 19th Annual BIO CEO and Investor Conference AmpliPhi Biosciences Corporation,
Published by
Business Wire
30 Jan 17 AmpliPhi Biosciences Appoints Dr. Igor P. Bilinsky as Senior Vice President and Chief Operating Officer AmpliPhi Biosciences Corporation,
Published by
Business Wire
04 Jan 17 Renowned Sinus Surgeon Dr. Peter-John Wormald Comments on AmpliPhi Biosciences’ Favorable Phase 1 Results of AB-SA01 in Chronic Rhinosinusitis Patients AmpliPhi Biosciences Corporation,
Published by
Business Wire
19 Dec 16 AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis Patients AmpliPhi Biosciences Corporation,
Published by
Business Wire
05 Dec 16 CORRECTING and REPLACING AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 AmpliPhi Biosciences Corporation,
Published by
Business Wire
05 Dec 16 AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 AmpliPhi Biosciences Corporation AmpliPhi Biosciences Corporation,
Published by
Business Wire
17 Nov 16 AmpliPhi Biosciences Announces Pricing of Public Offering of Common Stock and Warrants AmpliPhi Biosciences Corporation,
Published by
Business Wire
14 Nov 16 AmpliPhi Biosciences Announces Settlement of Pending Lawsuit AmpliPhi Biosciences Corporation,
Published by
Business Wire
01 Nov 16 AmpliPhi Biosciences Granted Small and Medium Enterprise Status by European Medicines Agency AmpliPhi Biosciences Corporation,
Published by
Business Wire
26 Oct 16 AmpliPhi Biosciences Announces Favorable Topline Safety and Tolerability Results from Its Phase 1 Trial in Patients with Chronic Rhinosinusitis AmpliPhi Biosciences ,
Published by
PharmiWeb.com
25 Oct 16 AmpliPhi Biosciences Announces Favorable Topline Safety and Tolerability Results from Its Phase 1 Trial in Patients with Chronic Rhinosinusitis AmpliPhi Biosciences Corporation,
Published by
Business Wire
17 Oct 16 AmpliPhi Biosciences Appoints Dr. Carrie-Lynn Langlais Furr as Vice President of Regulatory Affairs and Program Management AmpliPhi Biosciences Corporation,
Published by
Business Wire
20 Sep 16 AmpliPhi Biosciences Provides Update on Phase 1 Trial in Chronic Rhinosinusitis Patients AmpliPhi Biosciences Corporation,
Published by
Business Wire
01 Jun 16 AmpliPhi Biosciences Announces Pricing of Registered Direct Public Offering of Common Stock and Warrants AmpliPhi Biosciences Corporation,
Published by
Business Wire
12 May 16 AmpliPhi Biosciences Reports First Quarter 2016 Financial Results and Provides Corporate Update AmpliPhi Biosciences Corporation,
Published by
Business Wire
31 May 16 AmpliPhi Biosciences’ CEO to Discuss Novel Approaches to Fighting Drug-Resistant Pathogens in Panel at BIO International AmpliPhi Biosciences Corporation,
Published by
Business Wire
02 Jun 16 AmpliPhi Biosciences to be Granted European Patent Covering the Use of Phage Therapy to Resensitize Bacterial Infections To Antibiotics AmpliPhi Biosciences Corporation,
Published by
Business Wire
10 May 16 AmpliPhi Biosciences to Host Conference Call and Webcast Discussion of First Quarter 2016 Financial Results on May 13, 2016 AmpliPhi Biosciences Corporation,
Published by
Business Wire
04 Aug 16 AmpliPhi Biosciences Granted Japanese Patent Covering the Use of Phage Therapy to Resensitize Pseudomonas aeruginosa Infections to Antibiotics AmpliPhi Biosciences Corporation,
Published by
Business Wire
09 Aug 16 AmpliPhi Biosciences Confirms Clinical Trial Progress and Announces Upcoming Conference Call to Provide Corporate Update and Discuss Second Quarter 2016 Financial Results on August 15, 2016 AmpliPhi Biosciences Corporation,
Published by
Business Wire
03 Aug 16 AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus AmpliPhi Biosciences Corporation,
Published by
Business Wire
13 Sep 16 AmpliPhi Biosciences Announces Topline Results from Its Phase 1 Phage Therapy Trial Conducted in the United States AmpliPhi Biosciences,
Published by
Business Wire
13 Sep 16 AmpliPhi Biosciences’ Bacteriophage Cocktail Shown to Prevent C. difficile Biofilm Formation and Reduce Colonization AmpliPhi Biosciences,
Published by
PharmiWeb.com
24 May 16 AmpliPhi Biosciences Announces Start of First Phage Therapy Trial in U.S. Under IND AmpliPhi Biosciences Corporation,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.